Yeul Hong Kim, MD, PhD is the President of R&D at Yuhan corporation, Korea. Dr. Kim was Professor of Medical Oncology at the Korea University College of Medicine from 1995 to 2023. He is certified in internal medicine and medical oncology by the Korean Association of Internal Medicine. He graduated from the Korea University Medical College and received a PhD degree in the Korea University, Seoul Korea. He was a research fellow in the Department of Gastrointestinal Medical Oncology and Thoracic/Head and Neck Medical Oncology of the MD Anderson Cancer Center, Houston, Texas, USA.
Dr. Kim is primarily interested in the new drug development in precision medicine era. He is former President of Asian Oncology Society and he served as the Director of the Korean Precision Medicine Enterprise from 2017 to 2022, which was funded from Korea Ministry of Health and Welfare.

Oct 2024 - Present: Director, SCL-KAIST Institute of Translational Research
Sep 2024 - Present: Professor, Department of Bioengineering, KAIST
Sep 2014 - Aug 2024: Associate Professor, Department of Bioengineering, KAIST
Jan 2010 - Dec 2012: Principal Investigator, Genome Institute of Singapore (Joint appointment)
Oct 2009 - Aug 2014: Assistant Professor, Department of Bioengineering, KAIST

Oct 2024 - Present: Director, SCL-KAIST Institute of Translational Research
Sep 2024 - Present: Professor, Department of Bioengineering, KAIST
Sep 2014 - Aug 2024: Associate Professor, Department of Bioengineering, KAIST
Jan 2010 - Dec 2012: Principal Investigator, Genome Institute of Singapore (Joint appointment)
Oct 2009 - Aug 2014: Assistant Professor, Department of Bioengineering, KAIST

Chaok Seok is a Professor of Chemistry at Seoul National University, specializing in computational biology. Her research integrates deep learning and data-driven approaches to elucidate the structure and dynamics of biomolecules. After receiving her Ph.D. in theoretical chemistry from the University of Chicago, she began biomolecular modeling research at UCSF. Since joining Seoul National University in 2004, she has led the development of advanced methods for protein structure prediction and molecular interaction modeling. In 2020, she co-founded Galux, an AI-driven drug discovery startup, where she continues to lead innovation at the intersection of artificial intelligence and biopharmaceutical science.

Prof Namshik Han

Group Leader, Head of AI Research
Milner Therapeutics Institute, University of Cambridge

Faculty
Cambridge Centre for AI in Medicine, University of Cambridge

Affiliated Principal Investigator
Cambridge Stem Cell Institute, University of Cambridge

Professor
Department of Quantum Information, Yonsei University

Adjunct Professor
Department of Biomedical Systems Informatics, Yonsei University

CTO & Co-founder
CardiaTec Biosciences Ltd

A highly accomplished computational drug discovery scientist, I specialize in machine learning, computational biology, and multi-omics. I serve as Professor in the Department of Quantum Information at Yonsei University and Head of AI Research at the Milner Therapeutics Institute, University of Cambridge. My academic leadership spans both institutions, where I direct research labs focused on applying quantum computing to AI-driven drug discovery, pioneering efforts at the interface of quantum technologies and translational biomedicine.

At Cambridge, I also hold appointments as Faculty at the Cambridge Centre for AI in Medicine and as an Affiliated Principal Investigator at the Cambridge Stem Cell Institute. These roles support my broader mission of developing cutting-edge AI methods for deciphering complex multimodal biomedical data, enabling the discovery of novel disease pathways, mechanisms, and therapeutic targets.

Beyond academia, I am deeply committed to translating scientific innovation into impact. I actively collaborate with industry partners to apply AI in therapeutic development and patient care, ensuring that the tools and strategies developed in my labs accelerate progress across the biomedical landscape. I am a founding scientist of Storm Therapeutics and co-founder of two AI drug discovery companies: KURE.ai Therapeutics, which focuses on NK cell-based immunotherapies, and CardiaTec Biosciences, which targets breakthrough therapies for cardiovascular disease.

Responsible for Parexel Consulting, practices including Medical Affairs, Regulatory Consulting, Market Access, Health Economics & Outcomes Research, Medical Communications, & Clinical Development Strategy).
A seasoned drug development leader, prior to Parexel Consulting, Paul had a regulatory leadership role in biotech and before that was pharmaceutical assessor for the UK Licensing Authority and nominated EMA expert.
Awarded a Ph.D. for his published work in respiratory medicine, Paul is a pharmacist by training.

Eunbin Park is a Regulatory Affairs Team Manager at Yuhan Corporation, where she leads IND submissions for new molecular entities domestically and internationally. She holds a pharmacy degree from Seoul National University and brings over a decade of regulatory experience from leading pharmaceutical companies including Dong-A ST, Pfizer Korea, Astellas Japan, and Chugai Japan. Her expertise spans IND/NDA/BLA submissions for both biologics and small molecules across major markets including Korea, US, and EU.

Professional Summary

Over 15 years of progressive experience in clinical research and the pharmaceutical industry. Extensive experience in Phase I-IV studies, including global multi-regional clinical trials conducted in Asia, North America, Latin America, and Europe.

Education

M.S. in Public Health, The Catholic University of Korea (2018-2020)
B.S. in Pharmacy, Kyung Hee University (2003-2010)

Work Experience

Clinical Study Management II Team, Clinical Operation and Strategy, LG Chem (2011-Present)
Clinical Team, Green Cross (2009-2011)

Nick Costello serves as the Reference Safety Information Business Process Lead in Clinical Safety and Risk Management at Merck, Sharp & Dohme. Nick has over 10 years of experience in Clinical Safety and Pharmacovigilance, having worked with both clinical research organizations and pharmaceutical companies of varying sizes. Prior to joining the pharmaceutical industry, Nick practiced as a clinical hospital pharmacist. Nick has a Bachelor of Pharmacy from the University of Sydney, Australia and is pursuing a Master of Public Health.

Katerina Rok Song, MD, MPH is a research scientist in International Vaccine Institute (IVI). She graduated a medical school in Seoul, Korea, completed residency in Obstetrics & Gynecology, subspecialized in Obstetrics through fellowship. She started her vaccine career in a pharmaceutical company, Glaxosmithkline (GSK), with HPV vaccine and expanded her scope to all vaccines as a vaccine medical director in GSK Korea. She moved on to a public sector, Korea Disease Control Agency and worked in the department of national immunization program (NIP) and vaccine preventable diseases (VPD) as an epidemic intelligence service (EIS) officer/VPD team manager. Now Katerina is working in IVI, leading clinical trials as a project lead for the trials on cholera vaccines, COVID-19 vaccines and a Hepatitis E vaccine.

As CEO of Selta Square, a global leader in pharmacovigilance, Minkyung Shin leads the only company in Korea offering true end-to-end PV services along with an AI/Digital Transformation-based SaaS platform. With cross-functional expertise spanning regulation, data, and technology, she supports pharmaceutical and biotech companies in building lifecycle safety strategies. She also contributes to the global PV ecosystem through academic engagement and advisory roles.

Soyeon Hwang, PharmD, is a PV Part Manager at C&R Research with over 7 years of pharmacovigilance experience at C&R Research (CRO) and Korea Institute of Drug Safety & Risk Management (KIDS, Health Authority). She has comprehensive PV experience from clinical trials to post-marketing phases including safety data management, RMP and active surveillance, DSUR, Long term follow up study.

Jungran Ahn is a seasoned investor in the bio and healthcare sector and a licensed patent attorney, with over two decades of professional experience and an academic foundation in pharmacy (B.S. and M.S.). She currently holds the position of Managing Director at SJ Investment Partners, where she is responsible for leading venture investments in biotechnology and healthcare. Her previous roles include overseeing business development and intellectual property management at FirstBio Therapeutics, Inc., as well as serving in the Open Innovation Group at Handok, where she specialized in licensing and intellectual property strategy.

Education

Doctor of Philosophy, New York University, Sep 2004 - May 2009
Department of Environmental Health Sciences
Bachelor of Science, Seoul National University, Mar 1996 ? Feb 2000
School of Earth and Environmental Sciences


Professional Experience

BNH Investment, Jan 2018 ? Present (Seoul, Korea)
Venture Capital Fund Managing Director/Partner

CJ Corporation, Apr 2012 ? Dec 2017 (Seoul, Korea)
Senior Manager, Strategic Investment and Open Innovation

National Institutes of Health, Feb 2010 ? Mar 2012 (Maryland, USA)
Post-doctoral Fellow

HYUNKI KIM (Stonebridge Ventures Inc.)

03/2018 - Present, Managing Director, Stonebridge Ventures
04/2017 - 02/2018, Senior Manager, NS Investment
08/2014 - 03/2017, Senior Manager, Global Corporation Development, Dong-A ST
12/2006 - 07/2014, Research Scientist, Biotech research, Dong-A Socio Holdings

Dr. Yeojung Moon is a passionate investor at IMM Investment with various early-to-late stage investment experiences in bio and healthcare. As the first MD into the venture capital industry, she has guided various early-stage bio and healthcare startups to establish and grow their business into global scale. Leveraging her clinical and research experience at Yonsei Severance Hospital as an OBGYN doctor, she has been recognized as an early-detector of differentiated technology and hands-on supporter to her portfolio partners. Her track record is accentuated by her distinctive contribution to Lunit (KOSDAQ:A32813) as a multi-time investor and a board member(aka Lunit’s Mom) to realize their mission to “Conquer Cancer through AI”

She holds a board seat of Hanwha Investment & Securities Co., Ltd.(KOSPI: 003530) and is a selected member of Presidential committee of Korea’s 4th industrial revolution.

Prior to joining IMM, Dr. Moon led Bio investment division at InterVest. She was also an assistant professor at Yonsei Severance Hospital. Yeojung holds PhD in Neuroscience and MD from Yonsei University.

2019- Senior managing director, IMM Investment Corp.
2016-2018 Director, Intervest Co.
2004-2016 Clinical Professor, Severance Hospital, OBGYN
2014 Yonsei University, School of Medical Science, Ph.D
2004 Yonsei university, School of Medicine, MD

Liza Theron, PhD is an experienced Medical Writing professional and has held various writing and management roles since joining Parexel Medical Writing Services in January 2019. Prior to joining Parexel, she had 26 years' experience in quality assurance (QA) of documents and procedures in various sectors, including Marketing Research, Clinical Trials and Academia.
Her current role involves applying her writing and QA experience in the development and validation of AI tools in the generation of clinical documents, via prompt engineering within a Large Language Model based system.

Doyeon Kim began her clinical research career as a CRA and has since held roles such as Project Manager, Monitoring Manager, and Quality & Training Lead at various global pharmaceutical companies. Since 2019, she has worked at MSD Korea, currently serving as CRA Manager. In addition to project and people management, she has led initiatives to improve clinical operations, including the adoption of eISF. She holds a Life Sciences degree from Korea University.

Timothy Hajj, PharmD, is an Associate Director in Global Regulatory Affairs and Clinical Safety at Merck (Rahway, NJ), leading regulatory activities for digital innovation in clinical supply and providing regulatory insight and guidance to project teams related to drug development. Previously, he was a Global Regulatory Affairs Manager at Daiichi Sankyo, focusing on global regulatory strategy. He holds an A.S. in Chemistry from County College of Morris and a Doctor of Pharmacy from Rutgers.

CHRIS FANELLI, partner at Sidley, is former Associate Chief Counsel for Enforcement at the U.S. FDA and a partner in Sidley Austin LLP’s Food, Drug and Medical Device practice. Chris’ clients include pre-commercial and early-stage commercial biotech companies, CAR T and gene therapy manufacturers, finished drug and biologics manufacturers, combination product manufacturers, and investment funds contemplating investments in this highly regulated industry. Having spent a number of years at FDA advising agency personnel on enforcement and compliance matters, Chris routinely counsels pre-commercial and commercial biotech companies on compliance with FDA’s GxP requirements; data integrity and Part 11 responsibilities; compliance with FDA’s import and export requirements; and pharmacovigilance obligations. Chris also helps clients develop and implement strategies for responding to Deficiency Letters and Complete Response Letters involving facilities, quality, and CMC issues with a focus on minimizing adverse impact to the business while helping achieve compliance objectives.

KELLY CHO is a Senior Managing Associate at Sidley and advises clients on a wide range of FDA regulatory and compliance matters affecting drugs, biological products, medical devices, cosmetics, and other products regulated by the agency. Kelly regularly assists clients on questions that may arise throughout a product’s lifecycle with respect to marketing authorization pathways, clinical trials, expedited programs and designations, FDA’s application review and approval process, and regulatory exclusivities.

Hyok Jung Kim is an Associate Research Fellow at the Korea Institute for International Economic Policy (KIEP), where he is part of the North America and Europe Team. His recent publications at KIEP analyze the policy actions of the Trump 2.0 administration and the implications of reciprocal tariffs. Dr. Kim earned his Ph.D. in Economics from the University of California, Davis. Prior to joining KIEP, he worked as a researcher at the Korea Institute for Industrial Economics and Trade (KIET).

- Majored pharmacy in ChungAng University and its grade school. MBA in Dongguk University.
- Worked in MFDS, Yuhan Corporation, BMS Korea, Korea Otsuka, Kowa Korea, Bayer, Medpacto, and Freyr solutions, and has more than 25 years experience in drug regulatory affairs.
- With wide and in-depth regulatory affairs intelligence based on any regulatory changes in MFDS and experience in local and multinational pharmaceutical companies and health authority (MFDS), has been managed successful drug pipeline management including applications of NDA(BLA), DMF (API), IND, OTC, and other healthcare products.
- Managed pre-IND and pre-NDA meetings with MFDS, change applications related with labeling & CMC, review of promotional materials, and orphan drug designation application.
- Has US regulatory experience and knowledge in IND application, HA meeting, and orphan drug designation application with US FDA. RAC certificate (RAPS) in US regulation.

Jihye Ahn has 9 years of experience in applying quantitative tools to support new drug development and regulatory science as a Clinical Pharmacologist and Pharmacometrician in the US FDA. She is passionate about promoting MIDD approaches in oncologic and hematologic drug development. She is also a registered pharmacist in Maryland, USA. She received PharmD/MS in Pharmacometrics from University of Maryland. She holds MS and BE in Electrical Engineering.

Dr. Sang Hoon Lee founded ABL Bio in 2016 and built bispecific antibody-based portfolios for cancer and neurodegeneration. Prior to ABL, Dr. Lee co-founded PharmAbcine and led Hanwha Bio. He also brings years of experience from global biopharmaceutical companies, including Chiron (Novartis), AstraZeneca, Genentech, and Exelixis. Dr. Lee earned his Ph.D. at The Ohio State University and completed postdoctoral training at Harvard and Stanford.

Hee Chul Chang (Steven Chang) is a biotechnology and pharmaceutical expert with over 25 years of experience and a Ph.D. in Pharmacokinetics. He led R&D teams at Hanmi and Daewoong Pharmaceutical, and later served as Executive Director at Daewoong America, overseeing business development and licensing in North America. Now Managing Partner at Kairos Bioconsulting, he advises on global BD and M&A. He received Korea’s Best New Drug Development Researcher award and has led key licensing deals for antibodies, ADCs and small molecules.